Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI Effects on Body Composition in Endocrine Tumors
NCT02592356Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2015
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cabozantinib and lenvatinib in differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), pheochromocytoma and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Change in weight at 6 months. Started Nov 2015; status: completed.
02
Drugs
cabozantiniblenvatinib
03
Conditions
differentiated thyroid carcinoma (DTC)medullary thyroid carcinoma (MTC)pheochromocytomamalignant paraganglioma
Beyond the preview
Go deeper on NCT02592356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592356.